| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1006 | 2012 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 617* | 2019 |
| International Myeloma Working Group recommendations for the treatment of multiple myeloma–related bone disease E Terpos, G Morgan, MA Dimopoulos, MT Drake, S Lentzsch, N Raje, ... Journal of clinical oncology 31 (18), 2347, 2013 | 440 | 2013 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 434 | 2016 |
| Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, ... Journal of Clinical Oncology 33 (6), 657-664, 2015 | 414 | 2015 |
| Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group J Laubach, L Garderet, A Mahindra, G Gahrton, J Caers, O Sezer, ... Leukemia 30 (5), 1005-1017, 2016 | 288 | 2016 |
| Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label … S Grosicki, M Simonova, I Spicka, L Pour, I Kriachok, M Gavriatopoulou, ... The Lancet 396 (10262), 1563-1573, 2020 | 252 | 2020 |
| International Myeloma Working Group recommendations for global myeloma care H Ludwig, JS Miguel, MA Dimopoulos, A Palumbo, R Garcia Sanz, ... Leukemia 28 (5), 981-992, 2014 | 243 | 2014 |
| Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ... The Lancet Oncology 22 (3), e105-e118, 2021 | 190 | 2021 |
| Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications D Cibor, R Domagala-Rodacka, T Rodacki, A Jurczyszyn, T Mach, ... World journal of gastroenterology 22 (3), 1067, 2016 | 116 | 2016 |
| Central nervous system involvement by multiple myeloma: a multi‐institutional retrospective study of 172 patients in daily clinical practice A Jurczyszyn, N Grzasko, A Gozzetti, J Czepiel, A Cerase, V Hungria, ... American journal of hematology 91 (6), 575-580, 2016 | 115 | 2016 |
| Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma T Facon, JH Lee, P Moreau, R Niesvizky, M Dimopoulos, R Hajek, L Pour, ... Blood, The Journal of the American Society of Hematology 133 (18), 1953-1963, 2019 | 107 | 2019 |
| Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium R Ríos, CB Lupiañez, D Campa, A Martino, J Martínez-López, ... Endocrine-related cancer 22 (4), 545-559, 2015 | 98 | 2015 |
| HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA F Jiang, X Tang, C Tang, Z Hua, M Ke, C Wang, J Zhao, S Gao, ... Journal of hematology & oncology 14, 1-5, 2021 | 84 | 2021 |
| Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations L Rosiñol, M Beksac, E Zamagni, NWCJ Van de Donk, KC Anderson, ... British journal of haematology 194 (3), 496-507, 2021 | 83 | 2021 |
| Extramedullary disease in multiple myeloma: a systematic literature review J Bladé, M Beksac, J Caers, A Jurczyszyn, M von Lilienfeld-Toal, ... Blood Cancer Journal 12 (3), 45, 2022 | 77 | 2022 |
| Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients N Grzasko, M Hus, A Pluta, A Jurczyszyn, A Walter‐Croneck, M Morawska, ... Hematological oncology 31 (1), 41-48, 2013 | 62 | 2013 |
| Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients A Jurczyszyn, J Radocha, J Davila, MA Fiala, A Gozzetti, N Grząśko, ... British Journal of Haematology 180 (6), 831-839, 2018 | 60 | 2018 |
| Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2017 A Dmoszyńska, L Usnarska-Zubkiewicz, J Walewski, E Lech-Marańda, ... Acta Haematologica Polonica 48 (2), 55-103, 2017 | 58 | 2017 |
| Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma PN Munshi, D Vesole, A Jurczyszyn, JM Zaucha, A St. Martin, O Davila, ... Cancer 126 (23), 5077-5087, 2020 | 55 | 2020 |
Meletios Athanasios DimopoulosNational and Kapodistrian University of Athens, School of MedicineZweryfikowany adres z med.uoa.gr
